We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > obinutuzumab

News List

NICE recommends new chemo-free chronic lymphocytic leukaemia treatment europeanpharmaceuticalreview
November 16, 2020
More than 1,000 people each year could benefit from treatment with a combination of venetoclax and obinutuzumab, according to NICE.
AbbVie Receives EC Approval of VENCLYXTO Regimen for Lymphocytic Leukemia americanpharmaceuticalreview
March 16, 2020
AbbVie announced the European Commission (EC) has approved VENCLYXTO® (venetoclax) in combination with obinutuzumab for the treatment of adult patients with chronic lymphocytic leukemia (CLL) ...
Calquence significantly prolonged time patients lived without disease progression or death in previously untreated CLL pharmaceutical-business-review
December 11, 2019
AstraZeneca presented results from the interim analysis of the Phase III ELEVATE TN trial, showing that Calquence (acalabrutinib) combined with obinutuzumab or ...
ASCO: Combo Regimen Effective in CLL With Coexisting Conditions drugs
June 05, 2019
Combo Regimen Effective in CLL With Coexisting Conditions.
Imbruvica Plus Obinutuzumab Shown to Increase Survival for Leukemia/Lymphoma americanpharmaceuticalreview
December 05, 2018
Janssen Pharmaceutical announced results from the Phase 3 iLLUMINATE (PCYC-1130) study, which showed the combination of Imbruvica (ibrutinib) plus obinutuzumab......